The U.S. Supreme Court's June 24 ruling ending federal abortion rights under Roe v. Wade could inspire groups that seek to protect embryos to urge greater restrictions on in vitro fertilization (IVF) and embryonic stem cell research, according to Henry T. (Hank) Greely, director of the Stanford Law School Center for Biomedical Ethics.
Assisted reproductive technologies such as IVF aren't constitutionally protected and neither is preimplantation genetic testing, which screens for certain traits and DNA-caused conditions in embryos that haven't yet been implanted in the uterus, he said in a recent interview prior to the landmark ruling.
The court's ruling doesn't ban these technologies, which assist people seeking to have children, but it is likely to inspire some groups and states to seek to preserve unused embryos or ban embryonic stem cell research, Greely said.
His paper about the potential short- and long-term impacts of the decision is in preprint publication and is expected to be published in the Journal of Law and Biosciences in the coming weeks. In the short term, the technologies that embryo-protection groups might seek to ban or limit might be an alternative for women who can no longer receive an abortion in their home state.
Prenatal testing currently can determine if the fetus has a serious DNA defect that would cause disease or disability; a woman can then decide whether to continue with or terminate the pregnancy. That choice would likely disappear in states that restrict abortions, Greely said.
But a genetic testing technique that is used during in vitro fertilization could be utilized to prevent IVF pregnancies with fetal abnormalities. Preimplantation genetic testing, or PGT, screens out embryos with DNA-causing birth defects before the embryos are transferred to the uterus. The procedure can determine with a high degree of accuracy whether an embryo would develop into a baby who might have one of a large number of conditions. The decision not to transfer an embryo with genes that could cause a disability, condition or trait isn't illegal in the U.S., he said.
In states where abortion is illegal, it's likely there would be an increased interest in using PGT. The embryos are screened while outside the womb and prior to implantation and pregnancy.
"I think some people, some couples will say, well, if we have an embryo for the pregnancy that would have a severe disability as a child, our state wouldn't allow us to abort it. So let's go through preimplantation," he said.
But Greely doesn't think using PGT will skyrocket after the court's abortion decision. The technique requires that prospective parents use IVF, which is unpleasant and risky due to egg harvesting, he said.
IVF is also expensive. Most couples seeking the technique do so due to infertility and the decision isn't made lightly. Anyone with enough money to afford IVF would likely be able to afford to travel to another state for an abortion, he said.
Greely thinks it is unlikely embryo-protection groups would advocate for any kind of legislation that has a negative effect on IVF, however.
"Americans like IVF; almost everybody knows somebody or will know somebody who's either gone through IVF or who's actually the product of IVF. Two percent of the babies born every year in the U.S. with the product of IVF, and particularly the wealthier people are, the more likely they are to have either used IVF or know somebody who uses IVF, and also, the more likely they are to be politically powerful," he said.
There's a certain sort of law Greely thinks might be politically viable: limiting the selection or deselection of an embryo for IVF for a specific reason such as race, gender or disability.
"We've already seen it in abortion state statutes. A lot of abortion laws ban abortion for the purpose of discriminating on race, sex or disability status. And some of them explicitly say Down syndrome status.
"I can imagine the disability community coming together with protection groups to try to pass laws banning using PGT to select against embryos based on race, sex or disability. The important part of that would probably be disability and maybe even with the focus just on Down syndrome, which has a very strong support group and has some political sympathy," he said.
There isn't much political support for eliminating embryos that would have a fatal disease, however, he said.
"There's a more attractive case for protecting embryos that might become people with Down syndrome compared to protecting embryos that might become babies who would die within a year from Tay-Sachs disease," he said.
The court's decision on Roe v. Wade could invigorate efforts to pass new legislation to protect embryos outside the uterus among people who believe embryos are viable far earlier than at the 15 weeks in the Mississippi case that challenged Roe v. Wade. Some groups have claimed that human life starts far earlier and even at fertilization, which would make, in their view, all embryos for IVF "viable" regardless of whether they are implanted in the womb.
In the normal medical standard of care, no more than two embryos should be transferred into a woman's uterus at a time to minimize the chances of multiple pregnancies, Greely noted in his paper.
Most IVF cycles produce more than two eggs. Prospective parents can choose to have the extra embryos frozen for possible later use, donated to other couples, designated for research or destroyed and discarded.
Some legislation advocated by embryo-protection groups could limit or change the practice, he said. With the exception of Louisiana, there are no limitations on destroying embryos that aren't implanted, he said, though some other states have considered the legislation.
"The only limitation that I know of is the Louisiana law where you're not allowed to destroy embryos. So leftover embryos are kept frozen indefinitely in IVF clinics there," he said.
Legislation could lead clinics to build facilities to freeze and store unused embryos in perpetuity, he said, adding that the Louisiana law hasn't caused IVF clinics to close.
Embryo-protection groups might also try to get a law passed that's similar to a 2004 Italian law, which was subsequently limited by a court decision, Greely noted.
"They said you have to transfer for possible implantation every viable embryo you make, which means in Italy they typically only make one or two embryos at a time.
The embryo-protection groups "might try that, but all that would do is make IVF more difficult or expensive, and I don't think there's going to be political support for it. I don't think there'll be enough political support for it for people to adopt it," he said.
Greely noted that there could potentially be a significant change in embryo research as opposed to clinical treatments in an IVF clinic.
"Actually, embryo research in particular has really nothing to do with Roe v. Wade. As a matter of law, Roe v. Wade never protected embryo research, but I think it's connected in terms of the political dynamics after the death of Roe v. Wade," Greely said.
There's a good chance that at some stage, states will pass laws that eliminate human embryo research, in part because it is a huge issue, he said. Embryonic stem cells are taken from embryos created and then not used for pregnancy at IVF clinics.
"Twenty years ago, a number of states banned it; a number of states like California encouraged that research. But research into Type 1 diabetes and other major diseases has been disappointing.
"I think it has been useful, but there have been no miracles from it so far," he said.
The discovery in 2007 of a method to turn regular body cells into cells that can become any cell type in the human body makes the argument for using embryonic stem cells less compelling, he noted in his paper. Called induced pluripotent stem cells or iPSCs, these cells take away some of the urgency about using embryonic stem cells.
But iPSCs aren't exactly like human embryonic stem cells, Greely noted. Researchers would likely argue that human embryos are still required for research on embryonic development that would lead to ways for couples to succeed in having babies.
iPSCs might also play a role in the same types of research, since scientists have been creating "embryo-like things" or "embryo models" that provide more information about human embryonic development, he wrote.
How these laws might affect funding for embryonic research is also unknown.
The federal government has had little appetite for funding embryonic research and has refused to fund research that "destroys, discards, or knowingly subject(s) to risk of injury of death" embryos, Greely noted in his paper.
Yet, the federal government doesn't limit or ban the research itself; its actions have solely been about research it funds. Federal funds can be used for research on cells created from embryos that were destroyed somewhere else, he noted.
At least 11 states, however, have banned (or effectively banned) human embryo research on cells created from destroyed embryos that came from somewhere else, he wrote.
Some states allow such research, including California, Connecticut, Michigan, Montana and New York, Greely noted. California in particular continues to support stem cell research without a ban on the use of embryonic cells. In 2020, the state's voters passed Proposition 14 for $5.5 billion in bonds to advance the research.
See the article here:
How abortion ruling could affect IVF and embryonic research - The Almanac Online
- Breast Cancer Is Most Common Cancer In India, 1.38 Million Cases Diagnosed Annually. Know Estimated Incidence By 2030 - ABP Live - November 26th, 2023
- What Is Amyloidosis? All About The Rare Disease That Pervez Musharraf Suffered From - ABP Live - February 8th, 2023
- Autophagic death of neural stem cells mediates chronic stress-induced ... - November 7th, 2022
- Programmed cell death - Wikipedia - November 7th, 2022
- Hematopoietic Stem Cells | Hematopoiesis | Properties & Functions - September 4th, 2022
- Canadian Blood Services Stem Cells for Life - September 4th, 2022
- Devastation over death of schoolgirl, 11, who hoped she was beating cancer - Leicestershire Live - September 4th, 2022
- From optimized stem cell transplants to CAR T cell therapy: Advancing options for cancer, HIV and more - City of Hope - September 4th, 2022
- Scientists unlock the key to immortality in jellyfish - Syfy - September 4th, 2022
- Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients... - September 4th, 2022
- Menin Inhibitors Have Potential to Become the Next Class of Targeted Therapy in AML - Targeted Oncology - September 4th, 2022
- Wanted murder suspect John Belfield believed to still be in the UK as two more arrested over death of Thomas Campbell - The Manc - September 4th, 2022
- Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal... - July 8th, 2022
- Can minds persist when they are cut off from the world? - Livescience.com - July 8th, 2022
- Black Adolescent Young Adults With AML Have Worse Outcomes Vs White Population - Cancer Network - July 8th, 2022
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in... - July 8th, 2022
- This Morning viewers 'in tears' after boy meets donor who saved his life - Devon Live - July 8th, 2022
- Alpena detective: 'Good people out there' | News, Sports, Jobs - Alpena News - July 8th, 2022
- 'I miss my best friend': Five-year-old runs 10k to honour girl who died from rare brain tumour - Teesside Live - July 8th, 2022
- Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by... - July 8th, 2022
- Novartis AG, AstraZeneca Plc, and Pfizer Inc Among Leading Companies in the Thyroid Cancer Pipeline Products Market | Globaldata Plc - Yahoo Finance - July 8th, 2022
- A New Strategy Could Turn the Tide in Stem Cell GVHD - Medical Device and Diagnostics Industry - January 17th, 2022
- Vertex type 1 diabetes vs stem cell therapy - The Boar - January 17th, 2022
- Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT - AJMC.com Managed Markets Network - January 17th, 2022
- Nowakowski Considers CD19 Therapy in Transplant-Ineligible DLBCL - Targeted Oncology - January 17th, 2022
- Psaki demolishes Doocy with stats as he tries to claim covid now an illness of the vaccinated - newsconcerns - January 17th, 2022
- Doctors and Researchers Probe How COVID-19 Attacks the Heart - The Scientist - January 17th, 2022
- Who does donated blood that's direly needed help? - WTOP - January 17th, 2022
- Places Where Omicron is Most Contagious Eat This Not That - Eat This, Not That - January 17th, 2022
- UHN and U of T receive $24-million federal grant for transplant research - News@UofT - January 17th, 2022
- Glycyrrhizic acid ameliorates submandibular gland oxidative stress, autophagy and vascular dysfunction in rat model of type 1 diabetes | Scientific... - January 17th, 2022
- Stem cells in cancer therapy: opportunities and challenges - January 1st, 2022
- Life After Brain Death: Is the Body Still 'Alive'? | Live ... - January 1st, 2022
- Autologous Adult Stem Cells in the Treatment of Stroke | SCCAA - Dove Medical Press - January 1st, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 1st, 2022
- Cellular Therapies Fill Unmet Needs in R/R Multiple Myeloma - Targeted Oncology - January 1st, 2022
- Upregulated expression of actin-like 6A is a risk factor | CMAR - Dove Medical Press - January 1st, 2022
- COVID-19 Takes a Toll on People with Blood Cancers and Disorders - Cancer Health Treatment News - January 1st, 2022
- Mental health disorders and heart diseases - Rising Kashmir - January 1st, 2022
- Research breakthrough could mean better treatment for patients with most deadly form of brain tumor - EurekAlert - October 26th, 2021
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable... - October 26th, 2021
- European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 - Galveston County Daily News - October 26th, 2021
- Everything You Need To Know About COVID Booster Shots - Colorado Times Recorder - October 26th, 2021
- Stem cells and their role in lung transplant rejection - Michigan Medicine - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Will humans ever be immortal? - Livescience.com - October 5th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Why Bezos, Musk, Page and other billionaires want to live forever - New York Post - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - ABC 12 News - October 5th, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 5th, 2021
- Skeletons' broken clavicles tell a centuries-old tale of humans and horses - Massive Science - October 5th, 2021
- Environmental Factor - August 2021: Extramural Papers of the Month - Environmental Factor Newsletter - August 4th, 2021
- Role of traumatic brain injury in the development of glioma | JIR - Dove Medical Press - August 4th, 2021
- Targeted Therapeutics Market: Increase in Incidence of Cancer to Drive Global Market - BioSpace - August 4th, 2021
- Accumulation of Regulatory T Cells in Triple Negative Breast Cancer Ca | CMAR - Dove Medical Press - August 4th, 2021
- Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients with Multiple Myeloma - Curetoday.com - June 7th, 2021
- Autophagy suppresses the formation of hepatocyte-derived cancer-initiating ductular progenitor cells in the liver - Science Advances - June 7th, 2021
- Cancer research: New advances and innovations - Medical News Today - June 7th, 2021
- Fulvestrant Alone Found to be Superior to Venetoclax/Fulvestrant Combo in ER+/HER2- Breast Cancer - Targeted Oncology - June 7th, 2021
- Merck's KEYTRUDA Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal... - June 7th, 2021
- Stem cell study illuminates the cause of an inherited heart disorder | Penn Today - Penn Today - February 14th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with... - February 14th, 2021
- The Very First Signs of an Immune Response Have Been Filmed in a Developing Embryo - ScienceAlert - February 14th, 2021
- Arlo's Army needs stem cell donor as mum begs for help to save three-year-old's life - Glasgow Live - February 14th, 2021
- Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV (enfortumab vedotin-ejfv) in Patients with Previously... - February 14th, 2021
- [Full text] Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft | OTT - Dove Medical Press - February 14th, 2021
- The drug treatments offering the best hope of a way out of the Covid crisis - Telegraph.co.uk - February 14th, 2021
- In the war against Covid, an arsenal of drugs is on the way - Telegraph.co.uk - February 14th, 2021
- Kat Wests husband, Jeff West, sentenced to 16 years in wifes death - AL.com - February 9th, 2021
- Harnessing the Potential of Cell and Gene Therapy - OncLive - February 9th, 2021
- I Survived Cancer, and Then I Needed to Remember How to Live - The Atlantic - February 9th, 2021
- [Full text] Higher Red Blood Cell Distribution Width is a Poor Prognostic Factor f | CMAR - Dove Medical Press - February 9th, 2021
- West Belfast woman to be remembered in special TV documentary - Belfast Live - January 29th, 2021
- UTV documentary tells of young Belfast woman's lasting legacy to promote stem cell donation - The Irish News - January 29th, 2021
- L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL - Targeted Oncology - January 29th, 2021
- Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes... - January 29th, 2021
- If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? - Kaiser Health News - January 29th, 2021
- Experimental taphonomy of organelles and the fossil record of early eukaryote evolution - Science Advances - January 29th, 2021
- Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment - Business Wire - January 29th, 2021